<?xml version="1.0" encoding="UTF-8"?>
<TEI xml:space="preserve" xmlns="http://www.tei-c.org/ns/1.0" 
xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" 
xsi:schemaLocation="http://www.tei-c.org/ns/1.0 https://raw.githubusercontent.com/kermitt2/grobid/master/grobid-home/schemas/xsd/Grobid.xsd"
 xmlns:xlink="http://www.w3.org/1999/xlink">
	<teiHeader xml:lang="en">
		<fileDesc>
			<titleStmt>
				<title level="a" type="main">Tofacitinib versus methotrexate in rheumatoid arthritis: patient-reported outcomes from the randomised phase III ORAL Start trial</title>
			</titleStmt>
			<publicationStmt>
				<publisher/>
				<availability status="unknown"><licence/></availability>
				<date type="published" when="2016-09-28">28 September 2016</date>
			</publicationStmt>
			<sourceDesc>
				<biblStruct>
					<analytic>
						<author>
							<persName><forename type="first">Vibeke</forename><surname>Strand</surname></persName>
							<affiliation key="aff0">
								<orgName type="department">Division of Immunology/Rheumatology</orgName>
								<orgName type="institution">Stanford University School of Medicine</orgName>
								<address>
									<settlement>Palo Alto</settlement>
									<region>California</region>
									<country key="US">USA</country>
								</address>
							</affiliation>
						</author>
						<author>
							<persName><forename type="first">Eun</forename><forename type="middle">Bong</forename><surname>Lee</surname></persName>
							<affiliation key="aff1">
								<orgName type="department">Department of Internal Medicine</orgName>
								<orgName type="institution">Seoul National University College of Medicine</orgName>
								<address>
									<settlement>Seoul</settlement>
									<country key="KR">South Korea</country>
								</address>
							</affiliation>
						</author>
						<author>
							<persName><forename type="first">Roy</forename><surname>Fleischmann</surname></persName>
							<affiliation key="aff2">
								<orgName type="department">Department of Medicine</orgName>
								<orgName type="institution">University of Texas Southwestern Medical Center</orgName>
							</affiliation>
							<affiliation key="aff3">
								<orgName type="institution">Metroplex Clinical Research Center</orgName>
								<address>
									<settlement>Dallas</settlement>
									<region>Texas</region>
									<country key="US">USA</country>
								</address>
							</affiliation>
						</author>
						<author>
							<persName><forename type="first">Rieke</forename><forename type="middle">E</forename><surname>Alten</surname></persName>
							<affiliation key="aff4">
								<orgName type="department" key="dep1">Department of Internal Medicine</orgName>
								<orgName type="department" key="dep2">Schlosspark-Klinik</orgName>
								<orgName type="institution">University Medicine Berlin</orgName>
								<address>
									<settlement>Rheumatology, Berlin</settlement>
									<country key="DE">Germany</country>
								</address>
							</affiliation>
						</author>
						<author>
							<persName><forename type="first">Tamas</forename><surname>Koncz</surname></persName>
							<affiliation key="aff5">
								<orgName type="department">Global Innovative Pharmaceuticals</orgName>
								<address>
									<settlement>Pfizer</settlement>
									<region>New York, New York</region>
									<country key="US">USA</country>
								</address>
							</affiliation>
						</author>
						<author>
							<persName><forename type="first">Samuel</forename><forename type="middle">H</forename><surname>Zwillich</surname></persName>
							<affiliation key="aff6">
								<orgName type="department">Global Innovative Pharmaceuticals</orgName>
								<address>
									<settlement>Pfizer, Groton</settlement>
									<region>Connecticut</region>
									<country key="US">USA</country>
								</address>
							</affiliation>
						</author>
						<author>
							<persName><forename type="first">David</forename><surname>Gruben</surname></persName>
							<affiliation key="aff6">
								<orgName type="department">Global Innovative Pharmaceuticals</orgName>
								<address>
									<settlement>Pfizer, Groton</settlement>
									<region>Connecticut</region>
									<country key="US">USA</country>
								</address>
							</affiliation>
						</author>
						<author>
							<persName><forename type="first">Bethanie</forename><surname>Wilkinson</surname></persName>
							<affiliation key="aff6">
								<orgName type="department">Global Innovative Pharmaceuticals</orgName>
								<address>
									<settlement>Pfizer, Groton</settlement>
									<region>Connecticut</region>
									<country key="US">USA</country>
								</address>
							</affiliation>
						</author>
						<author>
							<persName><forename type="first">Sriram</forename><surname>Krishnaswami</surname></persName>
							<affiliation key="aff6">
								<orgName type="department">Global Innovative Pharmaceuticals</orgName>
								<address>
									<settlement>Pfizer, Groton</settlement>
									<region>Connecticut</region>
									<country key="US">USA</country>
								</address>
							</affiliation>
						</author>
						<author role="corresp">
							<persName><roleName>Dr</roleName><forename type="first">Gene</forename><surname>Wallenstein</surname></persName>
							<email>gene.wallenstein@pfizer.com</email>
							<affiliation key="aff6">
								<orgName type="department">Global Innovative Pharmaceuticals</orgName>
								<address>
									<settlement>Pfizer, Groton</settlement>
									<region>Connecticut</region>
									<country key="US">USA</country>
								</address>
							</affiliation>
						</author>
						<author>
							<persName><roleName>PhD</roleName><forename type="first">Anne</forename><forename type="middle">Marie</forename><surname>Reid</surname></persName>
						</author>
						<author>
							<persName><forename type="first">Pfizer</forename><forename type="middle">Andrew</forename><surname>Anisfeld</surname></persName>
						</author>
						<author>
							<persName><forename type="first">Elaine</forename><surname>Hoffman</surname></persName>
						</author>
						<author>
							<persName><forename type="first">Ryan</forename><surname>Demasi</surname></persName>
						</author>
						<author>
							<persName><forename type="first">Lisy</forename><surname>Wang</surname></persName>
						</author>
						<title level="a" type="main">Tofacitinib versus methotrexate in rheumatoid arthritis: patient-reported outcomes from the randomised phase III ORAL Start trial</title>
					</analytic>
					<monogr>
						<imprint>
							<date type="published" when="2016-09-28">28 September 2016</date>
						</imprint>
					</monogr>
					<idno type="MD5">F1F7BC7AA37F4E14BA62AA6B2F228108</idno>
					<idno type="DOI">10.1136/rmdopen-2016-000308</idno>
					<note type="submission">Received 12 May 2016 Revised 28 July 2016 Accepted 5 August 2016</note>
				</biblStruct>
			</sourceDesc>
		</fileDesc>
		<encodingDesc>
			<appInfo>
				<application version="0.7.2-SNAPSHOT" ident="GROBID" when="2022-05-18T11:23+0000">
					<desc>GROBID - A machine learning software for extracting information from scholarly documents</desc>
					<ref target="https://github.com/kermitt2/grobid"/>
				</application>
			</appInfo>
		</encodingDesc>
		<profileDesc>
			<textClass>
				<keywords>NCT01039688</keywords>
			</textClass>
			<abstract>
<div xmlns="http://www.tei-c.org/ns/1.0"><p><s>Objectives: To compare patient-reported outcomes (PROs) in methotrexate (MTX)-naive patients (defined as no prior treatment or ≤3 doses) receiving tofacitinib versus MTX.</s></p></div>
<div xmlns="http://www.tei-c.org/ns/1.0"><head>Methods:</head><p><s>In the 24-month, phase III, randomised, controlled, ORAL Start trial (NCT01039688), patients were randomised 2:2:1 to receive tofacitinib 5 mg two times per day (n=373), tofacitinib 10 mg two times per day (n=397) or MTX (n=186).</s><s>PROs assessed included Patient Global Assessment of disease (PtGA), pain, Health Assessment Questionnaire-Disability Index (HAQ-DI), Functional Assessment of Chronic Illness Therapy-Fatigue (FACIT-F) and health-related quality of life (Short Form-36 [SF-36]).</s></p><p><s>Results: PROs improved following tofacitinib and MTX treatment: benefits were sustained over 24 months.</s><s>Patients receiving tofacitinib reported earlier responses which were significantly different between each tofacitinib dose and MTX at month 3 through month 24.</s><s>At month 6 ( primary end point), significant improvements versus MTX were observed in PtGA, pain, HAQ-DI, SF-36 Physical Component Summary (PCS), 5/8 domain scores and FACIT-F with tofacitinib 5 mg two times per day; all PROs, except SF-36 Mental Component Summary Score and Medical Outcomes Survey-Sleep, with tofacitinib 10 mg two times per day.</s><s>At month 6, the proportion of patients reporting improvements ≥minimum clinically important difference were significant versus MTX with tofacitinib 5 mg two times per day in PtGA and 3/8 SF-36 domains; and with tofacitinib 10 mg two times per day in PtGA, pain, HAQ-DI, SF-36 PCS, 4/8 domains and FACIT-F.</s></p><p><s>Conclusions: Patients with rheumatoid arthritis receiving tofacitinib 5 and 10 mg two times per day monotherapy versus MTX reported statistically significant and clinically meaningful improvements in multiple PROs over 24 months; onset of benefit with tofacitinib treatment occurred earlier.</s></p></div>
			</abstract>
		</profileDesc>
	</teiHeader>
	<text xml:lang="en">
		<body>
<div xmlns="http://www.tei-c.org/ns/1.0"><head>INTRODUCTION</head><p><s>Rheumatoid arthritis (RA) is a chronic and debilitating autoimmune disease characterised by systemic inflammation, persistent synovitis and joint destruction.</s><s>RA affects all aspects of health-related quality of life (HRQoL). <ref type="bibr">1 2</ref></s><s>]<ref type="bibr" target="#b10">[11]</ref> Furthermore, the importance of incorporating PROs into the design of randomised controlled trials (RCTs) has been emphasised by Outcome Measures in Rheumatology (OMERACT) international consensus effort, American College of Rheumatology (ACR) and European League Against Rheumatism (EULAR). <ref type="bibr">7 12-15</ref></s><s>y messages ▸ Both tofacitinib monotherapy doses and MTX improved PROs; however, patients treated with tofacitinib reported earlier responses.</s><s>▸ Significant differences in improvement between tofacitinib and MTX were evident by month 3 and persisted.</s><s>▸ Improvements ≥MCID at month 6 were significant with tofacitinib versus MTX for multiple PROs.</s></p><p><s>Tofacitinib is an oral Janus kinase ( JAK) inhibitor for treatment of RA.</s><s>Tofacitinib preferentially inhibits signalling by heterodimeric receptors associated with JAK3 and JAK1, with functional selectivity over receptors that signal via pairs of JAK2. <ref type="bibr">16 17</ref></s><s>Tofacitinib 5 and 10 mg two times per day have been investigated in six phase III RCTs as monotherapy or in combination with conventional disease-modifying antirheumatic drugs (DMARDs), predominantly methotrexate (MTX), in patients with RA. <ref type="bibr" target="#b17">[18]</ref><ref type="bibr" target="#b18">[19]</ref><ref type="bibr" target="#b19">[20]</ref><ref type="bibr" target="#b20">[21]</ref><ref type="bibr" target="#b21">[22]</ref><ref type="bibr" target="#b22">[23]</ref> This RCT, ORAL Start, was designed to investigate the effects of tofacitinib monotherapy versus MTX in patients who were MTX-naive (defined as no prior treatment or ≤3 doses) over 24 months.</s><s>This phase III RCT (ClinicalTrials.gov</s><s>ID NCT01039688; Pfizer protocol A3921069) demonstrated that tofacitinib monotherapy resulted in clinically and statistically significant reductions in signs and symptoms of RA, improvements in PF and statistically significant inhibition of progression of structural damage compared with MTX, reported previously. <ref type="bibr" target="#b20">21</ref></s><s>The safety profile was similar to that previously reported in tofacitinib trials.</s><s>Here we report the PRO data from this RCT.</s></p></div>
<div xmlns="http://www.tei-c.org/ns/1.0"><head>METHODS</head></div>
<div xmlns="http://www.tei-c.org/ns/1.0"><head>Trial design and patients</head><p><s>This RCT was conducted across 151 centres worldwide; full details have been reported previously. <ref type="bibr" target="#b20">21</ref></s><s>Patients were ≥18 years of age with a diagnosis of RA according to the ACR 1987 Revised Criteria <ref type="bibr" target="#b23">24</ref> and active disease, defined as ≥6 tender and swollen joints (of 68/66 joints examined), with either erythrocyte sedimentation rate &gt;28 mm/hour (Westergren method) or C reactive protein &gt;7 mg/L.</s><s>Patients were randomised (2:2:1) to receive tofacitinib 5 mg two times per day or tofacitinib 10 mg two times per day monotherapy (hereafter referred to as tofacitinib 5 mg and tofacitinib 10 mg), or MTX starting at 10 mg/week, increasing in increments of 5 mg/week every month to 20 mg/week by week 8.</s></p><p><s>The trial was designed to detect differences between MTX and tofacitinib 5 or 10 mg in two primary efficacy end points at month 6: ACR70 response rates (at least 90% power) and inhibition of structural damage, measured by change from baseline in modified total Sharp score.</s><s>All other (efficacy) assessments were predefined as secondary end points.</s><s>After the publication of the results, one of its study sites (eight patients randomised) was found non-compliant to study procedures and those patients have been removed from the PRO analyses presented here.</s></p><p><s>The trial was approved by Institutional Review Boards (IRBs) and/or Independent Ethics Committees at each investigational centre or a central IRB, and conducted in accordance with the Declaration of Helsinki and International Conference on Harmonisation Good Clinical Practice Guidelines.</s><s>All patients provided written informed consent.</s></p></div>
<div xmlns="http://www.tei-c.org/ns/1.0"><head>Assessment of PROs</head><p><s>The following PROs (components of the ACR response criteria) were included as predefined end points: Patient Global Assessment of disease (PtGA), pain (assessed by 100 mm visual analogue scales (VAS)) and physical function by Health Assessment Questionnaire-Disability Index (HAQ-DI).</s><s>Other predefined secondary end points included HRQoL using Medical Outcomes Survey (MOS) Short Form-36 (SF-36; V.2, acute) questionnaire, fatigue by Functional Assessment of Chronic Illness Therapy-Fatigue (FACIT-F) scale and quality of sleep using MOS-Sleep scale. <ref type="bibr">25 26</ref></s><s>inimum clinically important differences (MCIDs) were defined as: ≥10 mm decreases from baseline in PtGA and pain VAS scores; 27 ≥0.22 point decrease from baseline in HAQ-DI; <ref type="bibr">15 25</ref> ≥2.5 point increases from baseline in SF-36 Physical Component Summary (PCS) and MCS scores; ≥5 point increases from baseline in SF-36 domain scores; <ref type="bibr">15 25</ref> and a 4-point increase from baseline in FACIT-F. <ref type="bibr" target="#b24">25</ref></s><s>MCID is not available for MOS-Sleep. <ref type="bibr" target="#b27">28</ref></s><s>tGA, pain, HAQ-DI and SF-36 scores were measured at all time points (baseline, months 1, 2, 3, 6, 9, 12, 15, 18, 21 and 24); FACIT-F and MOS-Sleep at baseline, months 1, 2, 3, 6, 12, 18 and 24.</s><s>The proportion of patients reporting improvements ≥MCID were compared between tofacitinib and MTX treatment groups at months 3, 6, 12 and 24.</s></p></div>
<div xmlns="http://www.tei-c.org/ns/1.0"><head>Statistical analyses</head><p><s>End points were expressed as mean changes from baseline and analysed using a linear mixed-effects repeatedmeasures model.</s><s>This model was based on the full analysis set (FAS; all patients who received ≥1 dose of study drug and with ≥1 postbaseline assessment).</s><s>Treatment, visit, treatment-by-visit interaction and baseline were included as fixed effects, as well as disease duration at baseline and region of investigative site; patients were included as random effects, employing the method of maximum likelihood using least squares (LS) estimates for parameters such as mean changes from baseline (for each treatment) as well as mean differences (each tofacitinib treatment vs MTX), hereafter LS mean (LSM).</s><s>Corresponding SEs for these estimates were also derived.</s></p><p><s>The percentage of patients reporting improvements ≥MCID and scores meeting or exceeding normative values were compared between tofacitinib and MTX treatment groups using the normal approximation to the binomial (FAS, no imputation).</s><s>All end points presented were prespecified, except for percentages of patients reporting improvements ≥MCID for FACIT-F and percentages of patients whose scores met or exceeded normative values.</s></p><p><s>Statistical significance was declared at p&lt;0.05, with no correction for multiple comparisons.</s></p><p><s>Number needed to treat (NNT; the number of patients who need to be treated for one patient to achieve an improvement in outcome) was calculated as 1/( proportion of patients in the tofacitinib group</s></p></div>
<div xmlns="http://www.tei-c.org/ns/1.0"><head>RESULTS</head></div>
<div xmlns="http://www.tei-c.org/ns/1.0"><head>Patients</head><p><s>Of 958 patients randomised, 373 received tofacitinib 5 mg, 397 tofacitinib 10 mg and 186 MTX (total=956).</s><s>Two hundred and ninety-eight patients discontinued treatment: 80 (43.0%) with MTX compared with 107 (28.7%) and 111 (28.0%) for tofacitinib 5 and 10 mg, respectively.</s><s>Most common reasons for discontinuation were adverse events with tofacitinib 5 mg (n=38) and tofacitinib 10 mg (n=39), and lack of efficacy with MTX (n=26).</s></p></div>
<div xmlns="http://www.tei-c.org/ns/1.0"><head>Baseline values</head><p><s>Prior treatments, patient demographics and baseline disease characteristics were similar across treatment groups. <ref type="bibr" target="#b20">21</ref></s><s>Mean disease duration was 2.7-3.4 years; 65.5% and 53.9% of patients had disease duration &lt;2 years and &lt;1 year, respectively.</s><s>Baseline mean PtGA, pain and HAQ-DI scores indicated impaired physical function (table <ref type="table" target="#tab_0">1</ref>).</s><s>Large decrements in reported</s></p><p><s>Figure <ref type="figure">1</ref> Spydergrams displaying SF-36 domains at months 3, 6, 12 and 24.</s><s>Study values were normed using population mean and SDs. <ref type="bibr">51 52</ref></s><s> HRQoL were evident by PCS scores ∼1.5-2.0</s><s>SDs below the normative score of 50, and lower domain scores compared with an age-matched and gender-matched US non-disease population (figure <ref type="figure">1</ref>).</s></p></div>
<div xmlns="http://www.tei-c.org/ns/1.0"><head>Patient-reported outcomes Patient Global Assessment of Disease activity</head><p><s>Patients who received tofacitinib 5 or 10 mg reported improvements from baseline in PtGA that were significant ( p&lt;0.05) versus MTX at all time points from month 1 to month 24 (table 1 and figure 2A); maximal effects were observed by month 6.</s><s>Compared with MTX, significantly more ( p&lt;0.05) patients who received tofacitinib reported improvements ≥MCID at months 3, 6, 12 and 24 (figure <ref type="figure" target="#fig_2">3A</ref>).</s><s>NNTs ranged from 7.2 to 10.4 with tofacitinib 5 mg and from 5.9 to 9.7 with tofacitinib 10 mg (figure <ref type="figure" target="#fig_1">3</ref>).</s></p></div>
<div xmlns="http://www.tei-c.org/ns/1.0"><head>Pain</head><p><s>Significant improvements from baseline in pain ( p&lt;0.05) versus MTX were seen at all time points from month 1 for patients who received tofacitinib 10 mg and at all time points with the exception of month 6 for those receiving tofacitinib 5 mg (table 1 and figure <ref type="figure" target="#fig_0">2B</ref>).</s><s>At months 3, 6 and 12, more patients ( p&lt;0.05) receiving tofacitinib 10 mg reported improvements ≥MCID versus MTX.</s><s>NNTs were lower with tofacitinib 10 mg compared with tofacitinib 5 mg, ranging from 7.3 to 10.2 (figure <ref type="figure" target="#fig_2">3B</ref>).</s></p><p><s>Health Assessment Questionnaire-Disability Index Patients receiving tofacitinib reported improvements from baseline in HAQ-DI that were significant ( p&lt;0.05) versus MTX at all time points from month 1 to month 24 (table 1 and figure <ref type="figure" target="#fig_2">3C</ref>).</s><s>Significantly ( p&lt;0.05) more</s></p></div>
<div xmlns="http://www.tei-c.org/ns/1.0"><head>Functional Assessment of Chronic Illness Therapy-Fatigue</head><p><s>Patients who received tofacitinib reported significant ( p&lt;0.05) improvements from baseline in FACIT-F versus MTX at all time points from month 1 (table 1 and figure <ref type="figure" target="#fig_0">2</ref>).</s><s>At month 3, significantly more patients in both tofacitinib groups reported improvements ≥MCID in FACIT-F versus MTX ( p&lt;0.05); at month 6, significant improvements were evident with tofacitinib 10 mg but not with tofacitinib 5 mg (figure <ref type="figure" target="#fig_2">3D</ref>).</s><s>NNTs at all time points were lower with tofacitinib 10 mg than with tofacitinib 5 mg (figure <ref type="figure" target="#fig_2">3D</ref>).</s><s>At months 6, 12 and 24, significantly ( p&lt;0.05) more patients receiving tofacitinib 10 mg two times per day versus MTX reported scores ≥normative values for FACIT-F (table 2); significant improvement was evident with tofacitinib 5 mg two times per day at month 12.</s></p></div>
<div xmlns="http://www.tei-c.org/ns/1.0"><head>HRQoL by SF-36</head><p><s>Patients in both tofacitinib treatment arms reported LSM changes from baseline in PCS scores that were significant ( p&lt;0.001) versus MTX at months 3, 6, 12 and 24.</s><s>The proportion of patients reporting improvements ≥MCID in PCS scores was significant ( p&lt;0.05) versus MTX at month 3 for both tofacitinib doses and months 6, 12 and 24 for tofacitinib 10 mg (table <ref type="table" target="#tab_0">1</ref>).</s><s>LSM changes from baseline in MCS scores with tofacitinib exceeded MTX at months 3, 6, 12 and 24, but were significant ( p&lt;0.05) versus MTX at month 3 for tofacitinib 5 mg and month 12 for tofacitinib 10 mg (table <ref type="table" target="#tab_0">1</ref>).</s><s>The proportion of patients receiving tofacitinib 10 mg who reported improvements ≥MCID in MCS scores was significant ( p&lt;0.05) versus MTX at months 12 and 24 (figure <ref type="figure" target="#fig_2">3E</ref>).</s><s>NNTs were therefore lower with tofacitinib 10 mg versus tofacitinib 5 mg for PCS and MCS scores.</s><s>Significant ( p&lt;0.05) improvements versus MTX were reported with tofacitinib 5 mg in PF, Role Physical (RP) and Bodily Pain (BP; months 3, 6, 12 and 24), GH (months 3 and 24), Vitality (VT) and Mental Health (MH) (months 3, 6 and 12), SF (months 3, 12 and 24) and Role Emotional (RE; month 3) domains (table <ref type="table" target="#tab_0">1</ref>).</s><s>Patients who received tofacitinib 10 mg reported significant improvements versus MTX in PF, RP, BP, GH, VT, SF and RE (months 3, 6, 12 and 24), and MH (months 6 and 12) domains (table <ref type="table" target="#tab_0">1</ref>).</s><s>Significantly more ( p&lt;0.05) patients who received tofacitinib 5 or 10 mg (vs MTX) reported improvements ≥MCID in all SF-36 domains at month 3. Additionally, significantly more patients reported improvements ≥MCID with tofacitinib 5 mg in PF, BP and MH domains at month 6, PF, BP and SF domains at month 12 and PF domain at month 24; and with tofacitinib 10 mg in PF, RP, BP and RE domains at month 6, PF, BP, SF, RE and MH domains at month 12 and PF, BP, VT, SF and MH at month 24 (figure <ref type="figure" target="#fig_2">3E</ref>).</s><s>Across SF-36 domains, NNTs were generally lower with tofacitinib 10 mg than with tofacitinib 5 mg (figure <ref type="figure" target="#fig_2">3E</ref>).</s><s>Significantly more ( p&lt;0.05) patients reported scores ≥normative values with tofacitinib 5 and 10 mg two times per day in PF, RP, BP, VT and MH domains at month 6 (table <ref type="table" target="#tab_3">2</ref>), PF, RP, SF and BP domains at month 12, and PF and BP domains at month 24 compared with MTX.</s></p></div>
<div xmlns="http://www.tei-c.org/ns/1.0"><head>Medical Outcomes Survey-Sleep</head><p><s>In general, compared with MTX, patients in both tofacitinib treatment arms reported numerically greater improvements from baseline in MOS-Sleep scores at all The number displayed within each treatment group is the percentage of patients reporting improvements ≥MCID (number of patients achieving MCID divided by the total number of patients in that treatment group).</s><s>The number displayed in parentheses is the NNT of that treatment compared with MTX.</s><s>*p&lt;0.05;</s><s>**p&lt;0.001;</s><s>***p&lt;0.0001</s><s>vs MTX.</s><s>All data are FAS, no imputation.</s><s>BID, two times a day; FACIT-F, Functional Assessment of Chronic Illness Therapy-Fatigue; FAS, full analysis set; HAQ-DI, Health Assessment Questionnaire-Disability Index; HRQoL, health-related quality of life; MCID, minimum clinically important difference; MTX, methotrexate; NA, not applicable (ie, NNT is negative); NNT, numbers needed to treat; Pain, Patient Assessment of Arthritis Pain; SF-36, Short Form-36.</s><s>time points.</s><s>These changes were statistically significant versus MTX with tofacitinib 5 mg at months 3 and 12, but were not statistically significant versus MTX with tofacitinib 10 mg (table <ref type="table" target="#tab_0">1</ref>).</s></p></div>
<div xmlns="http://www.tei-c.org/ns/1.0"><head>Discussion</head><p><s>In this paper, we report PROs from the phase III ORAL Start trial, which investigated the effects of tofacitinib monotherapy at two doses versus MTX in patients with active RA.</s><s>This is the first investigation of tofacitinib monotherapy versus MTX in patients who were predominantly MTX-naive.</s><s>]<ref type="bibr" target="#b31">[32]</ref><ref type="bibr" target="#b32">[33]</ref><ref type="bibr" target="#b33">[34]</ref><ref type="bibr" target="#b34">[35]</ref> Patients in all active treatment groups reported improvements across multiple PROs.</s><s>However, onset of treatment effect occurred earlier with tofacitinib than with MTX.</s><s>Statistically significant differences between both tofacitinib doses and MTX were first evident as early as month 1 in the case of PtGA, pain, HAQ-DI and FACITF and months 3 and 6 in other outcomes.</s><s>The benefits persisted over the length of the trial.</s><s>In general across the PROs, the responses with tofacitinib 10 mg dose were numerically higher than those observed with tofacitinib 5 mg.</s></p><p><s>From the patient perspective, PF, pain, HRQoL and fatigue have been shown to be important outcomes in trials of active RA.</s><s>In this RCT, treatment with tofacitinib 5 and 10 mg resulted in statistically significant LSM changes from baseline ( p&lt;0.005 vs MTX) in PtGA, pain, HAQ-DI, SF-36 PCS and FACIT-F scores from month 3.</s><s>With only one exception ( pain at month 6 in patients receiving tofacitinib 5 mg), these changes remained significant through month 24.</s><s>In addition, clinically meaningful improvements over time were reported across all of these end points, most notably PtGA, although differences between treatment groups in the proportion reporting improvements ≥MCID were not consistently statistically significant.</s><s>Together, improvements in PROs were consistent with ACR responses previously reported with tofacitinib versus MTX in this RCT. <ref type="bibr" target="#b20">21</ref></s><s>n comparison with an age-matched and gendermatched normative population, patients enrolled in ORAL Start reported markedly diminished HRQoL at baseline, based on SF-36 domain scores, indicating a substantial burden of disease.</s><s>LSM changes from baseline and improvements ≥MCID in PCS and all SF-36 domains were statistically significant in tofacitinib-treated patients at month 3, except the MH domain with tofacitinib 10 mg.</s><s>LSM changes from baseline reported by tofacitinib-treated patients at subsequent time points were sustained through month 24, although not necessarily statistically significant versus MTX at later time points, when additional later improvements with MTX were evident-consistent with the known time course of benefit of MTX.</s></p><p><s>In general, NNT values over time were numerically lower with tofacitinib 10 mg compared with tofacitinib 5 mg.</s><s>It must be noted that although it is usual for NNTs to be calculated against a placebo control, in this analysis, NNT values were calculated in relation to the active control MTX.</s><s>For most PRO measures, NNT values increased over time, which may be a reflection of the improvement in PRO outcomes with MTX generally occurring later than with tofacitinib.</s></p><p><s>Data from RCTs have demonstrated that the onset of benefit with MTX treatment is most evident 6 months after treatment initiation, with maximal benefit observed at 9-12 months; <ref type="bibr" target="#b35">[36]</ref><ref type="bibr" target="#b36">[37]</ref><ref type="bibr" target="#b37">[38]</ref><ref type="bibr" target="#b38">[39]</ref> patients with earlier disease treated aggressively are more likely to respond.</s><s>As this trial population included a majority of patients with disease of &lt;1 year duration, and those randomised to MTX received aggressive treatment (10 mg/week titrated to 20 mg/ week by month 2), clinically meaningful responses would be expected with MTX.</s><s>Onset of benefit with tofacitinib treatment was more rapid than with MTX, reflected by statistically significant LSM changes from baseline ≥MCID for both tofacitinib doses versus MTX in all PROs at month 3, except pain, HAQ-DI and SF-36 MCS scores with tofacitinib 5 mg and SF-36 MCS score with tofacitinib 10 mg.</s><s>Across all PROs, maximal benefit was achieved by month 6 in both tofacitinib treatment arms compared with 9-12 months with MTX.</s></p><p><s>Improvements in HRQoL observed in this trial were of similar magnitude and tempo of onset as observed with biological agents plus MTX compared with MTX monotherapy in MTX-naive patients, as reported with adalimumab, etanercept, golimumab and infliximab. <ref type="bibr">38 40-46</ref></s><s>n a phase III clinical trial of adalimumab, PROs including HAQ-DI, SF-36 PCS and FACIT-F scores were significantly improved with adalimumab 40 mg every other week plus MTX versus MTX monotherapy. <ref type="bibr" target="#b46">46</ref></s><s>A higher percentage of patients reported improvements in HAQ-DI ≥MCID with rituximab plus MTX (30%) compared with placebo plus MTX (15%) at year 2. <ref type="bibr" target="#b47">47</ref> Similarly, treatment with abatacept 10 mg/kg plus MTX resulted in greater improvements in SF-36 PCS and MCS, SF-36 domain scores and FACIT-F than placebo plus MTX. <ref type="bibr">48 49</ref></s><s>Patients enrolled in the GO-BEFORE RCT reported similar improvements in HAQ-DI and SF-36 PCS regardless of whether they received golimumab 50 mg plus MTX or MTX monotherapy. <ref type="bibr" target="#b50">50</ref></s><s>The limitations of this study have been reported previously. <ref type="bibr" target="#b20">21</ref></s><s>n summary, in the ORAL Start phase III RCT, patients with moderately to severely active RA who were MTX-naive reported improvements in PROs with tofacitinib 5 and 10 mg monotherapy that were statistically superior to MTX at month 3, occurred earlier and persisted through 24 months' treatment.</s><s>These results provide further evidence that tofacitinib monotherapy not only improves signs and symptoms and inhibits progression of structural damage in RA but also improves pain, physical function, HRQoL and fatigue in a range of patient populations, and with more rapid onset of these benefits than MTX.</s></p></div><figure xmlns="http://www.tei-c.org/ns/1.0" xml:id="fig_0"><head>Figure 2</head><label>2</label><figDesc><div><p><s>Figure 2 Continued</s></p></div></figDesc></figure>
<figure xmlns="http://www.tei-c.org/ns/1.0" xml:id="fig_1"><head>Figure 3</head><label>3</label><figDesc><div><p><s>Figure 3 Percentage of patients reporting improvements ≥MCID and NNTs to achieve an MCID in (A) PtGA, (B) pain, (C) HAQ-DI, (D) FACIT-F and (E) SF-36 domains and summary scores.</s><s>In (E) (SF-36), each bar is divided by colour (white, black or grey) to represent the treatment groups.</s><s>The number displayed within each treatment group is the percentage of patients reporting improvements ≥MCID (number of patients achieving MCID divided by the total number of patients in that treatment group).</s><s>The number displayed in parentheses is the NNT of that treatment compared with MTX.</s><s>*p&lt;0.05;</s><s>**p&lt;0.001;</s><s>***p&lt;0.0001</s><s>vs MTX.</s><s>All data are FAS, no imputation.</s><s>BID, two times a day; FACIT-F, Functional Assessment of Chronic Illness Therapy-Fatigue; FAS, full analysis set; HAQ-DI, Health Assessment Questionnaire-Disability Index; HRQoL, health-related quality of life; MCID, minimum clinically important difference; MTX, methotrexate; NA, not applicable (ie, NNT is negative); NNT, numbers needed to treat; Pain, Patient Assessment of Arthritis Pain; SF-36, Short Form-36.</s></p></div></figDesc></figure>
<figure xmlns="http://www.tei-c.org/ns/1.0" xml:id="fig_2"><head>Figure 3</head><label>3</label><figDesc><div><p><s>Figure 3 Continued</s></p></div></figDesc><graphic coords="8,55.11,48.42,485.01,599.87" type="bitmap" /></figure>
<figure xmlns="http://www.tei-c.org/ns/1.0"><head></head><label></label><figDesc><div><p></p></div></figDesc><graphic coords="4,93.09,221.10,409.16,478.77" type="bitmap" /></figure>
<figure xmlns="http://www.tei-c.org/ns/1.0"><head></head><label></label><figDesc><div><p></p></div></figDesc><graphic coords="5,240.26,274.56,313.17,450.82" type="bitmap" /></figure>
<figure xmlns="http://www.tei-c.org/ns/1.0" type="table" xml:id="tab_0"><head>Table 1</head><label>1</label><figDesc><div><p><s><ref type="bibr" target="#b28">29</ref>Os at baseline and LSM changes from baseline at months 3, 6, 12 and 24(24.49)60.88(22.55)a</s><s>57.91 (24.33) -30.12 (1.19) b ** -31.79 (1.13) c *** -22.63 (1.67) -31.86 (1.20) d * -35.10 (1.15) e ** -27.67 (1.71) -32.94 (1.23) f * -34.63 (1.19) g *** -26.18 (1.80) -34.41 (1.29) h * -35.79 (1.24) Functional Assessment of Chronic Illness Therapy-Fatigue; FAS, full analysis set; GH, General Health; HAQ-DI, Health Assessment Questionnaire-Disability Index; LSM, least squares mean; MCS, Mental Component Score; MH, Mental Health; MOS, Medical Outcomes Study; MTX, methotrexate; Pain, Patient Assessment of Arthritis Pain; PCS, Physical Component Score; PF, Physical Functioning; PROs, patient-reported outcomes; RE, Role Emotional; RP, Role Physical; SF, Social Functioning; SF-36, Short Form-36; VT, Vitality.Strand V, et al.RMD Open 2016;2:e000308.doi:10.1136/rmdopen-2016-000308reportingimprovements</s><s>≥MCID minus the proportion of patients in the MTX group reporting improvements ≥MCID).29</s></p></div></figDesc><table><row><cell></cell><cell></cell><cell></cell><cell></cell><cell>Month 3</cell><cell></cell><cell></cell><cell>Month 6</cell><cell></cell><cell></cell><cell>Month 12</cell><cell></cell><cell></cell><cell>Month 24</cell><cell></cell></row><row><cell></cell><cell cols="2">Baseline mean (SD)</cell><cell></cell><cell cols="2">LSM change from baseline (SE)</cell><cell></cell><cell cols="2">LSM change from baseline (SE)</cell><cell></cell><cell cols="2">LSM change from baseline (SE)</cell><cell></cell><cell cols="2">LSM change from baseline (SE)</cell></row><row><cell></cell><cell>Tofacitinib</cell><cell>Tofacitinib</cell><cell></cell><cell></cell><cell></cell><cell></cell><cell></cell><cell></cell><cell></cell><cell></cell><cell></cell><cell></cell><cell></cell><cell></cell></row><row><cell>PRO</cell><cell>5 mg two</cell><cell>10 mg two</cell><cell></cell><cell>Tofacitinib</cell><cell>Tofacitinib</cell><cell></cell><cell>Tofacitinib</cell><cell>Tofacitinib</cell><cell></cell><cell>Tofacitinib</cell><cell>Tofacitinib</cell><cell></cell><cell>Tofacitinib</cell><cell>Tofacitinib</cell></row><row><cell></cell><cell>times per</cell><cell>times per</cell><cell></cell><cell>5 mg two</cell><cell>10 mg two</cell><cell></cell><cell>5 mg two</cell><cell>10 mg two</cell><cell></cell><cell>5 mg two</cell><cell>10 mg two</cell><cell></cell><cell>5 mg two</cell><cell>10 mg two</cell></row><row><cell></cell><cell>day</cell><cell>day</cell><cell>MTX</cell><cell>times per day</cell><cell>times per day</cell><cell>MTX</cell><cell>times per day</cell><cell>times per day</cell><cell>MTX</cell><cell>times per day</cell><cell>times per day</cell><cell>MTX</cell><cell>times per day</cell><cell>times per day</cell><cell>MTX</cell></row><row><cell></cell><cell>N=370</cell><cell>N=393</cell><cell>N=184</cell><cell>N=351</cell><cell>N=380</cell><cell>N=169</cell><cell>N=337</cell><cell>N=363</cell><cell>N=156</cell><cell>N=312</cell><cell>N=328</cell><cell>N=133</cell><cell>N=261</cell><cell>N=278</cell><cell>N=105</cell></row><row><cell>Patient Global Assessment</cell><cell cols="4">60.42 51)*</cell><cell>5.85 (0.49) p</cell><cell>4.33 (0.72)</cell><cell>6.43 (0.52)</cell><cell>6.49 (0.50) e</cell><cell>4.92 (0.74) q</cell><cell>6.27 (0.53)</cell><cell>6.60 (0.51) m *</cell><cell>4.69 (0.77) r</cell><cell>6.20 (0.55)</cell><cell>7.44 (0.53)</cell><cell>5.59 (0.83)</cell></row><row><cell cols="2">SF-36 domain</cell><cell></cell><cell></cell><cell></cell><cell></cell><cell></cell><cell></cell><cell></cell><cell></cell><cell></cell><cell></cell><cell></cell><cell></cell><cell></cell></row><row><cell>PF</cell><cell cols="3">30.13 (9.44) 31.58 (9.88) 32.04 (9.59)</cell><cell cols="2">9.17 (0.52)*** 10.16 (0.50) c ***</cell><cell>4.33 (0.73) j</cell><cell cols="2">9.73 (0.53)*** 11.37 (0.51)***</cell><cell cols="3">5.75 (0.75) 10.68 (0.54)** 12.71 (0.52) m ***</cell><cell cols="3">7.37 (0.78) 11.74 (0.56)** 13.04 (0.54)***</cell><cell>7.92 (0.83)</cell></row><row><cell>RP</cell><cell cols="3">33.43 (9.58) 34.10 (9.37) 33.88 (9.39)</cell><cell>8.86 (0.49)***</cell><cell>9.81 (0.46) c ***</cell><cell>5.27 (0.68) j</cell><cell cols="2">9.70 (0.49)** 10.64 (0.47)***</cell><cell>6.68 (0.69)</cell><cell cols="2">9.86 (0.50)* 11.74 (0.48)***</cell><cell cols="2">7.10 (0.72) 10.41 (0.52)*</cell><cell>12.26 (0.50)***</cell><cell>7.84 (0.77)</cell></row><row><cell>BP</cell><cell cols="3">33.19 (8.04) 33.23 (7.22) 33.77 (7.57) o</cell><cell cols="2">10.72 (0.48)*** 11.50 (0.46) c ***</cell><cell cols="2">6.89 (0.68) 11.00 (0.49)*</cell><cell>12.59 (0.47)***</cell><cell cols="3">8.46 (0.70) q 11.70 (0.50)** 13.35 (0.48)***</cell><cell cols="2">8.54 (0.73) r 12.18 (0.53)*</cell><cell>13.80 (0.51)***</cell><cell>9.19 (0.79)</cell></row><row><cell>GH</cell><cell cols="3">37.96 (9.01) 37.20 (8.56) 37.51 (8.56)</cell><cell>6.08 (0.41)*</cell><cell>6.45 (0.40) c **</cell><cell>3.95 (0.58) j</cell><cell>6.19 (0.42)</cell><cell>6.81 (0.40)*</cell><cell>4.99 (0.59)</cell><cell>6.12 (0.43)</cell><cell>7.21 (0.41)*</cell><cell>5.36 (0.62)</cell><cell>6.49 (0.44)*</cell><cell>7.41 (0.43)**</cell><cell>4.88 (0.66)</cell></row><row><cell>VT</cell><cell cols="3">41.79 (9.89) 41.55 (9.96) n 41.62 (9.49)</cell><cell>8.20 (0.50)**</cell><cell>8.84 (0.48) p ***</cell><cell>5.06 (0.70) j</cell><cell>8.41 (0.50)*</cell><cell>8.64 (0.48) e *</cell><cell>6.01 (0.71)</cell><cell>8.40 (0.51)*</cell><cell>9.37 (0.50)*</cell><cell>6.50 (0.75)</cell><cell>8.23 (0.54)</cell><cell>9.33 (0.52)*</cell><cell>6.62 (0.79)</cell></row><row><cell>SF</cell><cell cols="3">36.38 (11.35) 36.67 (11.10) 37.52 (11.33)</cell><cell>8.14 (0.51)**</cell><cell>7.86 (0.48) c *</cell><cell>5.22 (0.71) j</cell><cell>8.50 (0.51)</cell><cell>9.20 (0.49)*</cell><cell>6.99 (0.73)</cell><cell>8.54 (0.52)*</cell><cell>9.59 (0.50)***</cell><cell>5.87 (0.76)</cell><cell>9.09 (0.55)*</cell><cell>10.40 (0.53)**</cell><cell>6.94 (0.82)</cell></row><row><cell>RE</cell><cell cols="3">33.98 (13.36) 34.73 (13.09) 34.67 (12.61)</cell><cell>7.26 (0.57)*</cell><cell>7.64 (0.54) c **</cell><cell>4.35 (0.80) j</cell><cell>7.60 (0.57)</cell><cell>9.09 (0.55) **</cell><cell>5.70 (0.82)</cell><cell>7.65 (0.58)</cell><cell>9.30 (0.56)**</cell><cell>5.93 (0.85)</cell><cell>8.64 (0.61)</cell><cell>10.41 (0.59)**</cell><cell>6.62 (0.92)</cell></row><row><cell>MH</cell><cell cols="3">38.85 (11.92) 39.42 (11.77) n 39.72 (11.35)</cell><cell>6.64 (0.53)*</cell><cell>6.35 (0.50) p</cell><cell>4.66 (0.74) j</cell><cell>7.08 (0.53)*</cell><cell>6.79 (0.51) e *</cell><cell>4.63 (0.76)</cell><cell>7.31 (0.54)*</cell><cell>7.33 (0.52)*</cell><cell>5.28 (0.79)</cell><cell>6.81 (0.57)</cell><cell>8.02 (0.55)</cell><cell>6.38 (0.85)</cell></row><row><cell>FACIT-F</cell><cell cols="3">28.43 (10.94) 29.01 (10.73) 28.49 (10.57) o</cell><cell>8.19 (0.48) s **</cell><cell>8.72 (0.46) c ***</cell><cell>5.33 (0.67) t</cell><cell>8.83 (0.48)*</cell><cell>9.13 (0.46) e **</cell><cell>6.45 (0.69)</cell><cell>8.85 (0.49)*</cell><cell>9.17 (0.48) g *</cell><cell>6.91 (0.71)</cell><cell>8.94 (0.51)*</cell><cell>9.56 (0.49) i **</cell><cell>6.32 (0.76)</cell></row><row><cell cols="6">MOS-Sleep 42.68 (19.55) u 42.86 (20.56) a 42.99 (18.09) -12.60 (0.88) s * -11.12 (0.83) c</cell><cell cols="10">-9.11 (1.22) are</cell></row><row><cell cols="2">FAS, longitudinal model.</cell><cell></cell><cell></cell><cell></cell><cell></cell><cell></cell><cell></cell><cell></cell><cell></cell><cell></cell><cell></cell><cell></cell><cell></cell><cell></cell></row><row><cell cols="3">*p&lt;0.05; **p&lt;0.001; ***p&lt;0.0001 vs MTX.</cell><cell></cell><cell></cell><cell></cell><cell></cell><cell></cell><cell></cell><cell></cell><cell></cell><cell></cell><cell></cell><cell></cell><cell></cell></row><row><cell cols="12">a N=394; b N=348; c N=379; d N=335; e N=362; f N=310; g N=326; h N=260; i N=277; j N=170; k N=336; l N=311; m N=327; n N=392; o N=183; p N=378; q N=155; r N=132; s N=349; t N=168; u N=369; v N=276.</cell><cell></cell><cell></cell><cell></cell></row><row><cell cols="2">BP, Bodily Pain; FACIT-F,</cell><cell></cell><cell></cell><cell></cell><cell></cell><cell></cell><cell></cell><cell></cell><cell></cell><cell></cell><cell></cell><cell></cell><cell></cell><cell></cell></row></table><note><p><s>i * -28.95 (1.94) Pain 59.23 (23.86) 61.38 (23.06) a 59.00 (23.61) -30.04 (1.19) b ** -33.01 (1.13) c *** -22.77 (1.67) j -32.11 (1.20) k -35.35 (1.15) e ** -28.34 (1.71) -32.46 (1.23) l * -35.85 (1.19) m ** -27.98 (1.80) -34.79 (1.29)* -37.62 (1.25) i ** -29.67 (1.94) HAQ-DI 1.54 (0.64) 1.50 (0.67) 1.53 (0.65) -0.76 (0.03)*** -0.86 (0.03) c *** -0.48 (0.04) -0.84 (0.03)*** -0.94 (0.03) e *** -0.59 (0.04) -0.88 (0.03)** -0.98 (0.03) m *** -0.69 (0.04) -0.91 (0.03)** -1.02 (0.03)*** -0.71 (0.05) SF-36 PCS 32.82 (7.25) 33.19 (7.33) n 33.51 (7.83) o 9.26 (0.43)*** 10.34 (0.42) p *** 5.06 (0.61) 9.74 (0.44)*** 11.26 (0.42) e *** 6.66 (0.62) q 10.34 (0.45)** 12.37 (0.43) m *** 7.55 (0.65) r 11.14 (0.46)*** 12.49 (0.45)*** 7.72 (0.69) MCS 40.47 (12.05) 40.69 (11.76) n 40.86 (11.30) o 6.19 (0.j -11.76 (0.88) k -12.28 (0.84) -9.83 (1.25) -12.34 (0.90) l * -11.94 (0.87) m -9.20 (1.31) -11.57</s><s>(0.94) -11.80 (0.91) v -10.84 (1.40) Baseline data and LSM change from baseline data at months 6, 12 and 24 for HAQ-DI, and significance versus MTX, were reported previously 21 and are presented here for comparison.</s><s>Baseline values are descriptive; LSM change from baseline data</s></p></note></figure>
<figure xmlns="http://www.tei-c.org/ns/1.0" type="table" xml:id="tab_3"><head>Table 2</head><label>2</label><figDesc><div><p><s>Percentage of patients reporting scores ≥normative values for PROs at month 6 p&lt;0.05; **p&lt;0.001;</s><s>***p&lt;0.0001</s><s>vs MTX.</s><s>BP, Bodily Pain; FACIT-F, Functional Assessment of Chronic Illness Therapy-Fatigue; GH, General Health; HAQ-DI, Health Assessment Questionnaire-Disability Index; MH, Mental Health; MTX, methotrexate; PF, Physical Functioning; PROs, patient-reported outcomes; RE, Role Emotional; RP, Role Physical; SF, Social Functioning; SF-36, Short Form-36; VT, Vitality.</s></p></div></figDesc><table><row><cell></cell><cell>Tofacitinib</cell><cell>Tofacitinib</cell><cell></cell></row><row><cell></cell><cell>5 mg two</cell><cell>10 mg two</cell><cell></cell></row><row><cell></cell><cell>times per day</cell><cell>times per day</cell><cell>MTX</cell></row><row><cell></cell><cell>N=337</cell><cell>N=363</cell><cell>N=156</cell></row><row><cell cols="2">HAQ-DI, n (%) 149 (44.21)**</cell><cell cols="2">195 (53.72)*** 42 (26.92)</cell></row><row><cell>SF-36 domain,</cell><cell></cell><cell></cell><cell></cell></row><row><cell>n (%)</cell><cell></cell><cell></cell><cell></cell></row><row><cell>PF</cell><cell cols="3">99 (29.38)*** 133 (36.64)*** 22 (14.10)</cell></row><row><cell>RP</cell><cell>104 (30.86)*</cell><cell>133 (36.64)**</cell><cell>33 (22.15)</cell></row><row><cell>BP</cell><cell>122 (36.20)*</cell><cell cols="2">153 (42.15)*** 35 (22.44)</cell></row><row><cell>GH</cell><cell>109 (32.34)</cell><cell>111 (30.58)</cell><cell>38 (24.36)</cell></row><row><cell>VT</cell><cell>192 (56.97)*</cell><cell>209 (57.58)*</cell><cell>68 (43.59)</cell></row><row><cell>SF</cell><cell>144 (42.73)</cell><cell>166 (45.73)</cell><cell>65 (41.67)</cell></row><row><cell>RE</cell><cell>113 (33.53)</cell><cell>138 (38.02)</cell><cell>46 (29.49)</cell></row><row><cell>MH</cell><cell>142 (42.14)*</cell><cell>157 (43.25)*</cell><cell>45 (28.85)</cell></row><row><cell cols="2">FACIT-F, n (%) 147 (43.62)</cell><cell>183 (50.41)*</cell><cell>55 (35.26)</cell></row></table><note><p><s>*Strand V, et al.</s><s>RMD Open 2016;2:e000308.</s><s>doi:10.1136/rmdopen-2016-000308</s></p></note></figure>
			<note xmlns="http://www.tei-c.org/ns/1.0" place="foot">on May 17, 2022 by guest. Protected by copyright. http://rmdopen.bmj.com/ RMD Open: first published as 10.1136/rmdopen-2016-000308 on 28 September 2016. Downloaded from</note>
			<note xmlns="http://www.tei-c.org/ns/1.0" place="foot" n="6">Strand V, et al. RMD Open 2016;2:e000308. doi:10.1136/rmdopen-2016-000308 RMD Open on May 17, 2022 by guest. Protected by copyright. http://rmdopen.bmj.com/ RMD Open: first published as 10.1136/rmdopen-2016-000308 on 28 September 2016. Downloaded from</note>
		</body>
		<back>
			<div type="annex">
<div xmlns="http://www.tei-c.org/ns/1.0"><p><s>Funding This work was supported by Pfizer.</s></p><p><s>Competing interests VS and EBL are consultants for Pfizer.</s><s>REA and RF have received research grants and are consultants for Pfizer.</s><s>TK, SHZ, DG, BW, SK and GW are shareholders and employees of Pfizer.</s></p></div>
<div xmlns="http://www.tei-c.org/ns/1.0"><head>Ethics approval</head><p><s>The trial was approved by Institutional Review Boards (IRBs) and/or Independent Ethics Committees at each investigational centre or a central IRB.</s></p><p><s>Provenance and peer review Not commissioned; externally peer reviewed.</s></p></div>
<div xmlns="http://www.tei-c.org/ns/1.0"><head>Data sharing statement No additional data are available.</head><p><s>Open Access This is an Open Access article distributed in accordance with the Creative Commons Attribution Non Commercial (CC BY-NC 4.0) license, which permits others to distribute, remix, adapt, build upon this work noncommercially, and license their derivative works on different terms, provided the original work is properly cited and the use is non-commercial.</s><s>See: http:// creativecommons.org/licenses/by-nc/4.0/</s></p></div>			</div>
			<div type="references">

				<listBibl>

<biblStruct xml:id="b0">
	<analytic>
		<title level="a" type="main">Health-related quality of life in early rheumatoid arthritis: impact of disease and treatment response</title>
		<author>
			<persName><forename type="first">V</forename></persName>
		</author>
		<idno type="DOI">10.1136/rmdopen-2016-000308on28</idno>
		<idno>10.1136/rmdopen-2016-000308 on 28</idno>
		<ptr target="http://rmdopen.bmj.com/RMDOpen" />
	</analytic>
	<monogr>
		<title level="j">Am J Manag Care</title>
		<imprint>
			<biblScope unit="volume">2</biblScope>
			<biblScope unit="page" from="231" to="240" />
			<date type="published" when="2002">September 2016. 2016. September 2016. September 2016. 2002</date>
		</imprint>
	</monogr>
	<note>Open</note>
</biblStruct>

<biblStruct xml:id="b1">
	<analytic>
		<title level="a" type="main">Newer biological agents in rheumatoid arthritis: impact on health-related quality of life and productivity</title>
		<author>
			<persName><forename type="first">V</forename><surname>Strand</surname></persName>
		</author>
		<author>
			<persName><forename type="first">J</forename><forename type="middle">A</forename><surname>Singh</surname></persName>
		</author>
		<idno type="DOI">10.2165/11531980-000000000-00000</idno>
	</analytic>
	<monogr>
		<title level="j">Drugs</title>
		<imprint>
			<biblScope unit="volume">70</biblScope>
			<biblScope unit="page" from="121" to="145" />
			<date type="published" when="2010">2010</date>
		</imprint>
	</monogr>
</biblStruct>

<biblStruct xml:id="b2">
	<analytic>
		<title level="a" type="main">Determinants of discordance in patients&apos; and physicians&apos; rating of rheumatoid arthritis disease activity</title>
		<author>
			<persName><forename type="first">N</forename><forename type="middle">A</forename><surname>Khan</surname></persName>
		</author>
		<author>
			<persName><forename type="first">H</forename><forename type="middle">J</forename><surname>Spencer</surname></persName>
		</author>
		<author>
			<persName><forename type="first">E</forename><surname>Abda</surname></persName>
		</author>
		<idno type="DOI">10.1002/acr.20685</idno>
	</analytic>
	<monogr>
		<title level="j">Arthritis Care Res (Hoboken)</title>
		<imprint>
			<biblScope unit="volume">64</biblScope>
			<biblScope unit="page" from="206" to="214" />
			<date type="published" when="2012">2012</date>
		</imprint>
	</monogr>
</biblStruct>

<biblStruct xml:id="b3">
	<analytic>
		<title level="a" type="main">Identifying core domains to assess flare in rheumatoid arthritis: an OMERACT international patient and provider combined Delphi consensus</title>
		<author>
			<persName><forename type="first">S</forename><forename type="middle">J</forename><surname>Bartlett</surname></persName>
		</author>
		<author>
			<persName><forename type="first">S</forename><surname>Hewlett</surname></persName>
		</author>
		<author>
			<persName><forename type="first">C</forename><forename type="middle">O</forename><surname>Bingham</surname></persName>
		</author>
		<author>
			<persName><surname>Iii</surname></persName>
		</author>
		<idno type="DOI">10.1136/annrheumdis-2011-201201</idno>
	</analytic>
	<monogr>
		<title level="j">Ann Rheum Dis</title>
		<imprint>
			<biblScope unit="volume">71</biblScope>
			<biblScope unit="page" from="1855" to="1860" />
			<date type="published" when="2012">2012</date>
		</imprint>
	</monogr>
</biblStruct>

<biblStruct xml:id="b4">
	<analytic>
		<title level="a" type="main">Patient-physician discordance in global assessment in rheumatoid arthritis: a systematic literature review with metaanalysis</title>
		<author>
			<persName><forename type="first">C</forename><surname>Desthieux</surname></persName>
		</author>
		<author>
			<persName><forename type="first">A</forename><surname>Hermet</surname></persName>
		</author>
		<author>
			<persName><forename type="first">B</forename><surname>Granger</surname></persName>
		</author>
		<idno type="DOI">10.1002/acr.22902</idno>
	</analytic>
	<monogr>
		<title level="j">Arthritis Care Res (Hoboken)</title>
		<imprint>
			<date type="published" when="2016-04">2016. Apr 2016</date>
		</imprint>
	</monogr>
</biblStruct>

<biblStruct xml:id="b5">
	<analytic>
		<title level="a" type="main">The patient perspective on remission in rheumatoid arthritis: &apos;You&apos;ve got limits</title>
		<author>
			<persName><forename type="first">L</forename><forename type="middle">H</forename><surname>Van Tuyl</surname></persName>
		</author>
		<author>
			<persName><forename type="first">S</forename><surname>Hewlett</surname></persName>
		</author>
		<author>
			<persName><forename type="first">M</forename><surname>Sadlonova</surname></persName>
		</author>
		<idno type="DOI">10.1136/annrheumdis-2013-204798</idno>
	</analytic>
	<monogr>
		<title level="j">Ann Rheum Dis</title>
		<imprint>
			<biblScope unit="volume">74</biblScope>
			<biblScope unit="page" from="1004" to="1010" />
			<date type="published" when="2015">2015</date>
		</imprint>
	</monogr>
	<note>but you&apos;re back to being you again</note>
</biblStruct>

<biblStruct xml:id="b6">
	<analytic>
		<title level="a" type="main">Incorporating the patient perspective into outcome assessment in rheumatoid arthritisprogress at OMERACT 7</title>
		<author>
			<persName><forename type="first">J</forename><forename type="middle">R</forename><surname>Kirwan</surname></persName>
		</author>
		<author>
			<persName><forename type="first">S</forename><forename type="middle">E</forename><surname>Hewlett</surname></persName>
		</author>
		<author>
			<persName><forename type="first">T</forename><surname>Heiberg</surname></persName>
		</author>
	</analytic>
	<monogr>
		<title level="j">J Rheumatol</title>
		<imprint>
			<biblScope unit="volume">32</biblScope>
			<biblScope unit="page" from="2250" to="2256" />
			<date type="published" when="2005">2005</date>
		</imprint>
	</monogr>
</biblStruct>

<biblStruct xml:id="b7">
	<analytic>
		<title level="a" type="main">Remission in rheumatoid arthritis: working toward incorporation of the patient perspective at OMERACT 12</title>
		<author>
			<persName><forename type="first">L</forename><forename type="middle">H</forename><surname>Van Tuyl</surname></persName>
		</author>
		<author>
			<persName><forename type="first">M</forename><surname>Sadlonova</surname></persName>
		</author>
		<author>
			<persName><forename type="first">B</forename><surname>Davis</surname></persName>
		</author>
		<idno type="DOI">10.3899/jrheum.141113</idno>
	</analytic>
	<monogr>
		<title level="j">J Rheumatol</title>
		<imprint>
			<biblScope unit="volume">43</biblScope>
			<biblScope unit="page" from="203" to="207" />
			<date type="published" when="2016">2016</date>
		</imprint>
	</monogr>
</biblStruct>

<biblStruct xml:id="b8">
	<analytic>
		<title level="a" type="main">Relationship between clinical and patient-reported outcomes in a phase 3 trial of tofacitinib or MTX in MTX-naïve patients with rheumatoid arthritis</title>
		<author>
			<persName><forename type="first">R</forename><surname>Fleischmann</surname></persName>
		</author>
		<author>
			<persName><forename type="first">V</forename><surname>Strand</surname></persName>
		</author>
		<author>
			<persName><forename type="first">B</forename><surname>Wilkinson</surname></persName>
		</author>
		<idno type="DOI">10.1136/rmdopen-2015-000232</idno>
	</analytic>
	<monogr>
		<title level="j">RMD Open</title>
		<imprint>
			<biblScope unit="volume">2</biblScope>
			<biblScope unit="page">e000232</biblScope>
			<date type="published" when="2016">2016</date>
		</imprint>
	</monogr>
</biblStruct>

<biblStruct xml:id="b9">
	<analytic>
		<title level="a" type="main">Long-term radiographic and patient-reported outcomes based on clinical disease activity index responses with tofacitinib at 6 months</title>
		<author>
			<persName><forename type="first">V</forename><surname>Strand</surname></persName>
		</author>
		<author>
			<persName><forename type="first">A</forename><surname>Kavanaugh</surname></persName>
		</author>
		<author>
			<persName><forename type="first">A</forename><surname>Kivitz</surname></persName>
		</author>
	</analytic>
	<monogr>
		<title level="j">Ann Rheum Dis</title>
		<imprint>
			<date type="published" when="2016">2016</date>
		</imprint>
	</monogr>
</biblStruct>

<biblStruct xml:id="b10">
	<analytic>
		<title level="a" type="main">Long-term radiographic and patient-reported outcomes based on Clinical Disease Activity Index responses with tofacitinib at 6 months</title>
		<author>
			<persName><forename type="first">V</forename><surname>Strand</surname></persName>
		</author>
		<author>
			<persName><forename type="first">A</forename><surname>Kavanaugh</surname></persName>
		</author>
		<author>
			<persName><forename type="first">A</forename><surname>Kivitz</surname></persName>
		</author>
	</analytic>
	<monogr>
		<title level="m">Abstr 1633</title>
				<imprint>
			<date type="published" when="2015">2015</date>
			<biblScope unit="volume">67</biblScope>
		</imprint>
	</monogr>
</biblStruct>

<biblStruct xml:id="b11">
	<analytic>
		<title level="a" type="main">The American College of Rheumatology preliminary core set of disease activity measures for rheumatoid arthritis clinical trials. The Committee on Outcome Measures in Rheumatoid Arthritis Clinical Trials</title>
		<author>
			<persName><forename type="first">D</forename><forename type="middle">T</forename><surname>Felson</surname></persName>
		</author>
		<author>
			<persName><forename type="first">J</forename><forename type="middle">J</forename><surname>Anderson</surname></persName>
		</author>
		<author>
			<persName><forename type="first">M</forename><surname>Boers</surname></persName>
		</author>
	</analytic>
	<monogr>
		<title level="j">Arthritis Rheum</title>
		<imprint>
			<biblScope unit="volume">36</biblScope>
			<biblScope unit="page" from="729" to="740" />
			<date type="published" when="1993">1993</date>
		</imprint>
	</monogr>
</biblStruct>

<biblStruct xml:id="b12">
	<analytic>
		<title level="a" type="main">Elaboration of the preliminary Rheumatoid Arthritis Impact of Disease (RAID) score: a EULAR initiative</title>
		<author>
			<persName><forename type="first">L</forename><surname>Gossec</surname></persName>
		</author>
		<author>
			<persName><forename type="first">M</forename><surname>Dougados</surname></persName>
		</author>
		<author>
			<persName><forename type="first">N</forename><surname>Rincheval</surname></persName>
		</author>
		<idno type="DOI">10.1136/ard.2008.100271</idno>
	</analytic>
	<monogr>
		<title level="j">Ann Rheum Dis</title>
		<imprint>
			<biblScope unit="volume">68</biblScope>
			<biblScope unit="page" from="1680" to="1685" />
			<date type="published" when="2009">2009</date>
		</imprint>
	</monogr>
</biblStruct>

<biblStruct xml:id="b13">
	<analytic>
		<title level="a" type="main">Overview of the patient perspective at OMERACT 10-conceptualizing methods for developing patient-reported outcomes</title>
		<author>
			<persName><forename type="first">J</forename><forename type="middle">R</forename><surname>Kirwan</surname></persName>
		</author>
		<author>
			<persName><forename type="first">P</forename><forename type="middle">S</forename><surname>Tugwell</surname></persName>
		</author>
		<idno type="DOI">10.3899/jrheum.110388</idno>
	</analytic>
	<monogr>
		<title level="j">J Rheumatol</title>
		<imprint>
			<biblScope unit="volume">38</biblScope>
			<biblScope unit="page" from="1699" to="1701" />
			<date type="published" when="2011">2011</date>
		</imprint>
	</monogr>
</biblStruct>

<biblStruct xml:id="b14">
	<analytic>
		<title level="a" type="main">It&apos;s good to feel better but it&apos;s better to feel good and even better to feel good as soon as possible for as long as possible. Response criteria and the importance of change at OMERACT 10</title>
		<author>
			<persName><forename type="first">V</forename><surname>Strand</surname></persName>
		</author>
		<author>
			<persName><forename type="first">M</forename><surname>Boers</surname></persName>
		</author>
		<author>
			<persName><forename type="first">L</forename><surname>Idzerda</surname></persName>
		</author>
	</analytic>
	<monogr>
		<title level="j">J Rheumatol</title>
		<imprint>
			<biblScope unit="volume">38</biblScope>
			<biblScope unit="page" from="1720" to="1727" />
			<date type="published" when="2011">2011</date>
		</imprint>
	</monogr>
</biblStruct>

<biblStruct xml:id="b15">
	<analytic>
		<title level="a" type="main">Modulation of innate and adaptive immune responses by tofacitinib (CP-690,550)</title>
		<author>
			<persName><forename type="first">K</forename><surname>Ghoreschi</surname></persName>
		</author>
		<author>
			<persName><forename type="first">M</forename><forename type="middle">I</forename><surname>Jesson</surname></persName>
		</author>
		<author>
			<persName><forename type="first">X</forename><surname>Li</surname></persName>
		</author>
		<idno type="DOI">10.4049/jimmunol.1003668</idno>
	</analytic>
	<monogr>
		<title level="j">J Immunol</title>
		<imprint>
			<biblScope unit="volume">186</biblScope>
			<biblScope unit="page" from="4234" to="4243" />
			<date type="published" when="2011">2011</date>
		</imprint>
	</monogr>
</biblStruct>

<biblStruct xml:id="b16">
	<analytic>
		<title level="a" type="main">Anti-inflammatory activity and neutrophil reductions mediated by the JAK1/JAK3 inhibitor, CP-690,550, in rat adjuvant-induced arthritis</title>
		<author>
			<persName><forename type="first">D</forename><forename type="middle">M</forename><surname>Meyer</surname></persName>
		</author>
		<author>
			<persName><forename type="first">M</forename><forename type="middle">I</forename><surname>Jesson</surname></persName>
		</author>
		<author>
			<persName><forename type="first">X</forename><surname>Li</surname></persName>
		</author>
		<idno type="DOI">10.1186/1476-9255-7-41</idno>
	</analytic>
	<monogr>
		<title level="j">J Inflamm (Lond)</title>
		<imprint>
			<biblScope unit="volume">7</biblScope>
			<biblScope unit="page">41</biblScope>
			<date type="published" when="2010">2010</date>
		</imprint>
	</monogr>
</biblStruct>

<biblStruct xml:id="b17">
	<analytic>
		<title level="a" type="main">CP-690,550) in combination with methotrexate in patients with active rheumatoid arthritis with an inadequate response to tumour necrosis factor inhibitors: a randomised phase 3 trial</title>
		<author>
			<persName><forename type="first">G</forename><forename type="middle">R</forename><surname>Burmester</surname></persName>
		</author>
		<author>
			<persName><forename type="first">R</forename><surname>Blanco</surname></persName>
		</author>
		<author>
			<persName><forename type="first">C</forename><surname>Charles-Schoeman</surname></persName>
		</author>
		<idno type="DOI">10.1016/S0140-6736(12)61424-X</idno>
	</analytic>
	<monogr>
		<title level="j">Lancet</title>
		<imprint>
			<biblScope unit="volume">381</biblScope>
			<biblScope unit="page" from="451" to="460" />
			<date type="published" when="2013">2013</date>
		</imprint>
	</monogr>
</biblStruct>

<biblStruct xml:id="b18">
	<analytic>
		<title level="a" type="main">Placebo-controlled trial of tofacitinib monotherapy in rheumatoid arthritis</title>
		<author>
			<persName><forename type="first">R</forename><surname>Fleischmann</surname></persName>
		</author>
		<author>
			<persName><forename type="first">J</forename><surname>Kremer</surname></persName>
		</author>
		<author>
			<persName><forename type="first">J</forename><surname>Cush</surname></persName>
		</author>
		<idno type="DOI">10.1056/NEJMoa1109071</idno>
	</analytic>
	<monogr>
		<title level="j">N Engl J Med</title>
		<imprint>
			<biblScope unit="volume">367</biblScope>
			<biblScope unit="page" from="495" to="507" />
			<date type="published" when="2012">2012</date>
		</imprint>
	</monogr>
</biblStruct>

<biblStruct xml:id="b19">
	<analytic>
		<title level="a" type="main">Tofacitinib in combination with nonbiologic disease-modifying antirheumatic drugs in patients with active rheumatoid arthritis: a randomized trial</title>
		<author>
			<persName><forename type="first">J</forename><surname>Kremer</surname></persName>
		</author>
		<author>
			<persName><forename type="first">Z</forename><forename type="middle">G</forename><surname>Li</surname></persName>
		</author>
		<author>
			<persName><forename type="first">S</forename><surname>Hall</surname></persName>
		</author>
		<idno type="DOI">10.7326/0003-4819-159-4-201308200-00006</idno>
	</analytic>
	<monogr>
		<title level="j">Ann Intern Med</title>
		<imprint>
			<biblScope unit="volume">159</biblScope>
			<biblScope unit="page" from="253" to="261" />
			<date type="published" when="2013">2013</date>
		</imprint>
	</monogr>
</biblStruct>

<biblStruct xml:id="b20">
	<analytic>
		<title level="a" type="main">Tofacitinib versus methotrexate in rheumatoid arthritis</title>
		<author>
			<persName><forename type="first">E</forename><forename type="middle">B</forename><surname>Lee</surname></persName>
		</author>
		<author>
			<persName><forename type="first">R</forename><surname>Fleischmann</surname></persName>
		</author>
		<author>
			<persName><forename type="first">S</forename><surname>Hall</surname></persName>
		</author>
		<idno type="DOI">10.1056/NEJMoa1310476</idno>
	</analytic>
	<monogr>
		<title level="j">N Engl J Med</title>
		<imprint>
			<biblScope unit="volume">370</biblScope>
			<biblScope unit="page" from="2377" to="2386" />
			<date type="published" when="2014">2014</date>
		</imprint>
	</monogr>
</biblStruct>

<biblStruct xml:id="b21">
	<analytic>
		<title level="a" type="main">CP-690,550) in patients with rheumatoid arthritis receiving methotrexate: twelve-month data from a twenty-four-month phase III randomized radiographic study</title>
		<author>
			<persName><forename type="first">D</forename><surname>Van Der Heijde</surname></persName>
		</author>
		<author>
			<persName><forename type="first">Y</forename><surname>Tanaka</surname></persName>
		</author>
		<author>
			<persName><forename type="first">R</forename><surname>Fleischmann</surname></persName>
		</author>
		<idno type="DOI">10.1002/art.37816</idno>
	</analytic>
	<monogr>
		<title level="j">Arthritis Rheum</title>
		<imprint>
			<biblScope unit="volume">65</biblScope>
			<biblScope unit="page" from="559" to="570" />
			<date type="published" when="2013">2013</date>
		</imprint>
	</monogr>
</biblStruct>

<biblStruct xml:id="b22">
	<analytic>
		<title level="a" type="main">Tofacitinib or adalimumab versus placebo in rheumatoid arthritis</title>
		<author>
			<persName><forename type="first">R</forename><forename type="middle">F</forename><surname>Van Vollenhoven</surname></persName>
		</author>
		<author>
			<persName><forename type="first">R</forename><surname>Fleischmann</surname></persName>
		</author>
		<author>
			<persName><forename type="first">S</forename><surname>Cohen</surname></persName>
		</author>
		<idno type="DOI">10.1056/NEJMoa1112072</idno>
	</analytic>
	<monogr>
		<title level="j">N Engl J Med</title>
		<imprint>
			<biblScope unit="volume">367</biblScope>
			<biblScope unit="page" from="508" to="519" />
			<date type="published" when="2012">2012</date>
		</imprint>
	</monogr>
</biblStruct>

<biblStruct xml:id="b23">
	<analytic>
		<title level="a" type="main">The American Rheumatism Association 1987 revised criteria for the classification of rheumatoid arthritis</title>
		<author>
			<persName><forename type="first">F</forename><forename type="middle">C</forename><surname>Arnett</surname></persName>
		</author>
		<author>
			<persName><forename type="first">S</forename><forename type="middle">M</forename><surname>Edworthy</surname></persName>
		</author>
		<author>
			<persName><forename type="first">D</forename><forename type="middle">A</forename><surname>Bloch</surname></persName>
		</author>
		<idno type="DOI">10.1002/art.1780310302</idno>
	</analytic>
	<monogr>
		<title level="j">Arthritis Rheum</title>
		<imprint>
			<biblScope unit="volume">31</biblScope>
			<biblScope unit="page" from="315" to="324" />
			<date type="published" when="1988">1988</date>
		</imprint>
	</monogr>
</biblStruct>

<biblStruct xml:id="b24">
	<analytic>
		<title level="a" type="main">Responsiveness of patient reported outcomes including fatigue, sleep quality, activity limitation, and quality of life following treatment with abatacept for rheumatoid arthritis</title>
		<author>
			<persName><forename type="first">G</forename><surname>Wells</surname></persName>
		</author>
		<author>
			<persName><forename type="first">T</forename><surname>Li</surname></persName>
		</author>
		<author>
			<persName><forename type="first">L</forename><surname>Maxwell</surname></persName>
		</author>
		<idno type="DOI">10.1136/ard.2007.069690</idno>
	</analytic>
	<monogr>
		<title level="j">Ann Rheum Dis</title>
		<imprint>
			<biblScope unit="volume">67</biblScope>
			<biblScope unit="page" from="260" to="265" />
			<date type="published" when="2008">2008</date>
		</imprint>
	</monogr>
</biblStruct>

<biblStruct xml:id="b25">
	<analytic>
		<title level="a" type="main">Assessing quality of sleep in patients with rheumatoid arthritis</title>
		<author>
			<persName><forename type="first">G</forename><forename type="middle">A</forename><surname>Wells</surname></persName>
		</author>
		<author>
			<persName><forename type="first">T</forename><surname>Li</surname></persName>
		</author>
		<author>
			<persName><forename type="first">J</forename><forename type="middle">R</forename><surname>Kirwan</surname></persName>
		</author>
		<idno type="DOI">10.3899/jrheum.090362</idno>
	</analytic>
	<monogr>
		<title level="j">J Rheumatol</title>
		<imprint>
			<biblScope unit="volume">36</biblScope>
			<biblScope unit="page" from="2077" to="2086" />
			<date type="published" when="2009">2009</date>
		</imprint>
	</monogr>
</biblStruct>

<biblStruct xml:id="b26">
	<analytic>
		<title level="a" type="main">Physical function and health related quality of life: analysis of 2-year data from randomized, controlled studies of leflunomide, sulfasalazine, or methotrexate in patients with active rheumatoid arthritis</title>
		<author>
			<persName><forename type="first">V</forename><surname>Strand</surname></persName>
		</author>
		<author>
			<persName><forename type="first">D</forename><forename type="middle">L</forename><surname>Scott</surname></persName>
		</author>
		<author>
			<persName><forename type="first">P</forename><surname>Emery</surname></persName>
		</author>
	</analytic>
	<monogr>
		<title level="j">J Rheumatol</title>
		<imprint>
			<biblScope unit="volume">32</biblScope>
			<biblScope unit="page" from="590" to="601" />
			<date type="published" when="2005">2005</date>
		</imprint>
	</monogr>
</biblStruct>

<biblStruct xml:id="b27">
	<analytic>
		<title level="a" type="main">Sleep measures</title>
		<author>
			<persName><forename type="first">R</forename><forename type="middle">D</forename><surname>Hays</surname></persName>
		</author>
		<author>
			<persName><forename type="first">A</forename><forename type="middle">L</forename><surname>Stewart</surname></persName>
		</author>
	</analytic>
	<monogr>
		<title level="m">Measuring functioning and well being</title>
				<editor>
			<persName><forename type="first">A</forename><forename type="middle">L</forename><surname>Stewart</surname></persName>
		</editor>
		<editor>
			<persName><forename type="first">J</forename><forename type="middle">E</forename><surname>Ware</surname><genName>Jr</genName></persName>
		</editor>
		<meeting><address><addrLine>Durham (NC</addrLine></address></meeting>
		<imprint>
			<publisher>Duke University Press</publisher>
			<date type="published" when="1992">1992</date>
			<biblScope unit="page" from="235" to="239" />
		</imprint>
	</monogr>
</biblStruct>

<biblStruct xml:id="b28">
	<analytic>
		<title level="a" type="main">Number-needed-to-treat (NNT)-needs treatment with care</title>
		<author>
			<persName><forename type="first">P</forename><forename type="middle">M</forename><surname>Christensen</surname></persName>
		</author>
		<author>
			<persName><forename type="first">I</forename><forename type="middle">S</forename><surname>Kristiansen</surname></persName>
		</author>
		<idno type="DOI">10.1111/j.1742-7843.2006.pto_412.x</idno>
	</analytic>
	<monogr>
		<title level="j">Basic Clin Pharmacol Toxicol</title>
		<imprint>
			<biblScope unit="volume">99</biblScope>
			<biblScope unit="page" from="12" to="16" />
			<date type="published" when="2006">2006</date>
		</imprint>
	</monogr>
</biblStruct>

<biblStruct xml:id="b29">
	<analytic>
		<title level="a" type="main">Effects of tofacitinib on patient-reported outcomes in patients with active rheumatoid arthritis receiving stable dose methotrexate: results of two Phase 3 studies</title>
		<author>
			<persName><forename type="first">G</forename><surname>Burmester</surname></persName>
		</author>
		<author>
			<persName><forename type="first">D</forename><surname>Van Der Heijde</surname></persName>
		</author>
		<author>
			<persName><forename type="first">V</forename><surname>Strand</surname></persName>
		</author>
	</analytic>
	<monogr>
		<title level="j">Arthritis Rheum</title>
		<imprint>
			<biblScope unit="volume">64</biblScope>
			<biblScope unit="issue">10</biblScope>
			<biblScope unit="page">549</biblScope>
			<date type="published" when="2012">2012</date>
		</imprint>
	</monogr>
	<note>Suppl</note>
</biblStruct>

<biblStruct xml:id="b30">
	<analytic>
		<title level="a" type="main">Oral Scan effects of the oral JAK inhibitor tofacitinib in combination with methotrexate on patient reported outcomes in a 24-month phase 3 trial of active rheumatoid arthritis</title>
		<author>
			<persName><forename type="first">V</forename><surname>Strand</surname></persName>
		</author>
		<author>
			<persName><forename type="first">D</forename><surname>Van Der Heijde</surname></persName>
		</author>
		<author>
			<persName><forename type="first">Caf</forename><surname>Zerbini</surname></persName>
		</author>
	</analytic>
	<monogr>
		<title level="j">Arthritis Rheum</title>
		<imprint>
			<biblScope unit="volume">65</biblScope>
			<biblScope unit="page">S996</biblScope>
			<date type="published" when="2013">2013</date>
		</imprint>
	</monogr>
	<note>Abstract No. 2334 (abstract</note>
</biblStruct>

<biblStruct xml:id="b31">
	<analytic>
		<title level="a" type="main">The effects of the oral JAK inhibitor CP-690,550 on patient reported outcomes in a phase 3 study of active rheumatoid arthritis</title>
		<author>
			<persName><forename type="first">V</forename><surname>Strand</surname></persName>
		</author>
		<author>
			<persName><forename type="first">K</forename><surname>Kanik</surname></persName>
		</author>
		<author>
			<persName><forename type="first">C</forename><forename type="middle">A</forename><surname>Connell</surname></persName>
		</author>
	</analytic>
	<monogr>
		<title level="j">Ann Rheum Dis</title>
		<imprint>
			<biblScope unit="volume">70</biblScope>
			<biblScope unit="page">88</biblScope>
			<date type="published" when="2011">2011</date>
		</imprint>
	</monogr>
</biblStruct>

<biblStruct xml:id="b32">
	<analytic>
		<title level="a" type="main">CP-690,550) in combination with traditional disease-modifying anti-rheumatic drugs: patient-reported outcomes from a Phase 3 study in patients with active rheumatoid arthritis and an inadequate response to disease-modifying anti-rheumatic drugs</title>
		<author>
			<persName><forename type="first">V</forename><surname>Strand</surname></persName>
		</author>
		<author>
			<persName><forename type="first">J</forename><surname>Kremer</surname></persName>
		</author>
		<author>
			<persName><forename type="first">Z</forename><forename type="middle">G</forename><surname>Li</surname></persName>
		</author>
	</analytic>
	<monogr>
		<title level="j">Arthritis Rheum</title>
		<imprint>
			<biblScope unit="volume">63</biblScope>
			<biblScope unit="page" from="S1032" to="1033" />
			<date type="published" when="2011">2011</date>
		</imprint>
	</monogr>
</biblStruct>

<biblStruct xml:id="b33">
	<analytic>
		<title level="a" type="main">Effects of tofacitinib (CP-690,550), an oral Janus kinase inhibitor, or adalimumab on patient reported outcomes in a phase 3 study of active rheumatoid arthritis</title>
		<author>
			<persName><forename type="first">R</forename><forename type="middle">F</forename><surname>Van Vollenhoven</surname></persName>
		</author>
		<author>
			<persName><forename type="first">G</forename><surname>Wallenstein</surname></persName>
		</author>
		<author>
			<persName><forename type="first">E</forename><forename type="middle">B</forename><surname>Lee</surname></persName>
		</author>
		<idno type="DOI">10.1136/annrheumdis-2012-eular.2116</idno>
	</analytic>
	<monogr>
		<title level="j">Ann Rheum Dis</title>
		<imprint>
			<biblScope unit="volume">71</biblScope>
			<biblScope unit="page">206</biblScope>
			<date type="published" when="2012">2012</date>
		</imprint>
	</monogr>
</biblStruct>

<biblStruct xml:id="b34">
	<analytic>
		<title level="a" type="main">Effect of golimumab on patient-reported outcomes in rheumatoid arthritis: results from the GO-FORWARD study</title>
		<author>
			<persName><forename type="first">M</forename><forename type="middle">C</forename><surname>Genovese</surname></persName>
		</author>
		<author>
			<persName><forename type="first">C</forename><surname>Han</surname></persName>
		</author>
		<author>
			<persName><forename type="first">E</forename><forename type="middle">C</forename><surname>Keystone</surname></persName>
		</author>
		<idno type="DOI">10.3899/jrheum.111195</idno>
	</analytic>
	<monogr>
		<title level="j">J Rheumatol</title>
		<imprint>
			<biblScope unit="volume">39</biblScope>
			<biblScope unit="page" from="1185" to="1191" />
			<date type="published" when="2012">2012</date>
		</imprint>
	</monogr>
</biblStruct>

<biblStruct xml:id="b35">
	<analytic>
		<title level="a" type="main">A comparison of etanercept and methotrexate in patients with early rheumatoid arthritis</title>
		<author>
			<persName><forename type="first">J</forename><forename type="middle">M</forename><surname>Bathon</surname></persName>
		</author>
		<author>
			<persName><forename type="first">R</forename><forename type="middle">W</forename><surname>Martin</surname></persName>
		</author>
		<author>
			<persName><forename type="first">R</forename><forename type="middle">M</forename><surname>Fleischmann</surname></persName>
		</author>
		<idno type="DOI">10.1056/NEJM200011303432201</idno>
	</analytic>
	<monogr>
		<title level="j">N Engl J Med</title>
		<imprint>
			<biblScope unit="volume">343</biblScope>
			<biblScope unit="page" from="1586" to="1593" />
			<date type="published" when="2000">2000</date>
		</imprint>
	</monogr>
</biblStruct>

<biblStruct xml:id="b36">
	<analytic>
		<title level="a" type="main">The PREMIER study: a multicenter, randomized, double-blind clinical trial of combination therapy with adalimumab plus methotrexate versus methotrexate alone or adalimumab alone in patients with early, aggressive rheumatoid arthritis who had not had previous methotrexate treatment</title>
		<author>
			<persName><forename type="first">F</forename><forename type="middle">C</forename><surname>Breedveld</surname></persName>
		</author>
		<author>
			<persName><forename type="first">M</forename><forename type="middle">H</forename><surname>Weisman</surname></persName>
		</author>
		<author>
			<persName><forename type="first">A</forename><forename type="middle">F</forename><surname>Kavanaugh</surname></persName>
		</author>
		<idno type="DOI">10.1002/art.21519</idno>
	</analytic>
	<monogr>
		<title level="j">Arthritis Rheum</title>
		<imprint>
			<biblScope unit="volume">54</biblScope>
			<biblScope unit="page" from="26" to="37" />
			<date type="published" when="2006">2006</date>
		</imprint>
	</monogr>
</biblStruct>

<biblStruct xml:id="b37">
	<analytic>
		<title level="a" type="main">A comparison of the efficacy and safety of leflunomide and methotrexate for the treatment of rheumatoid arthritis</title>
		<author>
			<persName><forename type="first">P</forename><surname>Emery</surname></persName>
		</author>
		<author>
			<persName><forename type="first">F</forename><forename type="middle">C</forename><surname>Breedveld</surname></persName>
		</author>
		<author>
			<persName><forename type="first">E</forename><forename type="middle">M</forename><surname>Lemmel</surname></persName>
		</author>
		<idno type="DOI">10.1093/rheumatology/39.6.655</idno>
	</analytic>
	<monogr>
		<title level="j">Rheumatology (Oxford)</title>
		<imprint>
			<biblScope unit="volume">39</biblScope>
			<biblScope unit="page" from="655" to="665" />
			<date type="published" when="2000">2000</date>
		</imprint>
	</monogr>
</biblStruct>

<biblStruct xml:id="b38">
	<analytic>
		<title level="a" type="main">Comparison of tocilizumab monotherapy versus methotrexate monotherapy in patients with moderate to severe rheumatoid arthritis: the AMBITION study</title>
		<author>
			<persName><forename type="first">G</forename><surname>Jones</surname></persName>
		</author>
		<author>
			<persName><forename type="first">A</forename><surname>Sebba</surname></persName>
		</author>
		<author>
			<persName><forename type="first">J</forename><surname>Gu</surname></persName>
		</author>
		<idno type="DOI">10.1136/ard.2008.105197</idno>
	</analytic>
	<monogr>
		<title level="j">Ann Rheum Dis</title>
		<imprint>
			<biblScope unit="volume">69</biblScope>
			<biblScope unit="page" from="88" to="96" />
			<date type="published" when="2010">2010</date>
		</imprint>
	</monogr>
</biblStruct>

<biblStruct xml:id="b39">
	<monogr>
		<title level="m" type="main">Treatment of active rheumatoid arthritis with leflunomide compared with placebo and methotrexate</title>
		<author>
			<persName><forename type="first">V</forename><surname>Strand</surname></persName>
		</author>
		<author>
			<persName><forename type="first">S</forename><surname>Cohen</surname></persName>
		</author>
		<author>
			<persName><forename type="first">M</forename><surname>Schiff</surname></persName>
		</author>
		<imprint/>
	</monogr>
</biblStruct>

<biblStruct xml:id="b40">
	<analytic>
		<title level="a" type="main">Leflunomide Rheumatoid Arthritis Investigators Group</title>
	</analytic>
	<monogr>
		<title level="j">Arch Intern Med</title>
		<imprint>
			<biblScope unit="volume">159</biblScope>
			<biblScope unit="page" from="2542" to="2550" />
			<date type="published" when="1999">1999</date>
		</imprint>
	</monogr>
</biblStruct>

<biblStruct xml:id="b41">
	<analytic>
		<title level="a" type="main">Function and health-related quality of life: results from a randomized controlled trial of leflunomide versus methotrexate or placebo in patients with active rheumatoid arthritis. Leflunomide Rheumatoid Arthritis Investigators Group</title>
		<author>
			<persName><forename type="first">V</forename><surname>Strand</surname></persName>
		</author>
		<author>
			<persName><forename type="first">P</forename><surname>Tugwell</surname></persName>
		</author>
		<author>
			<persName><forename type="first">C</forename><surname>Bombardier</surname></persName>
		</author>
		<idno type="DOI">10.1002/1529-0131(199909)42:9&lt;1870::AID-ANR11&gt;3.0.CO;2-D</idno>
	</analytic>
	<monogr>
		<title level="j">Arthritis Rheum</title>
		<imprint>
			<biblScope unit="volume">42</biblScope>
			<biblScope unit="page" from="1870" to="1878" />
			<date type="published" when="1999">1999</date>
		</imprint>
	</monogr>
</biblStruct>

<biblStruct xml:id="b42">
	<analytic>
		<title level="a" type="main">Combination of infliximab and methotrexate therapy for early rheumatoid arthritis: a randomized, controlled trial</title>
		<author>
			<persName><forename type="first">E</forename><forename type="middle">W</forename><surname>St Clair</surname></persName>
		</author>
		<author>
			<persName><forename type="first">D</forename><forename type="middle">M</forename><surname>Van Der Heijde</surname></persName>
		</author>
		<author>
			<persName><forename type="first">J</forename><forename type="middle">S</forename><surname>Smolen</surname></persName>
		</author>
		<idno type="DOI">10.1002/art.20568</idno>
	</analytic>
	<monogr>
		<title level="j">Arthritis Rheum</title>
		<imprint>
			<biblScope unit="volume">50</biblScope>
			<biblScope unit="page" from="3432" to="3443" />
			<date type="published" when="2004">2004</date>
		</imprint>
	</monogr>
</biblStruct>

<biblStruct xml:id="b43">
	<analytic>
		<title level="a" type="main">Patient reported outcomes in a trial of combination therapy with etanercept and methotrexate for rheumatoid arthritis: the TEMPO trial</title>
		<author>
			<persName><forename type="first">D</forename><surname>Van Der Heijde</surname></persName>
		</author>
		<author>
			<persName><forename type="first">L</forename><surname>Klareskog</surname></persName>
		</author>
		<author>
			<persName><forename type="first">A</forename><surname>Singh</surname></persName>
		</author>
		<idno type="DOI">10.1136/ard.2005.035709</idno>
	</analytic>
	<monogr>
		<title level="j">Ann Rheum Dis</title>
		<imprint>
			<biblScope unit="volume">65</biblScope>
			<biblScope unit="page" from="328" to="334" />
			<date type="published" when="2006">2006</date>
		</imprint>
	</monogr>
</biblStruct>

<biblStruct xml:id="b44">
	<analytic>
		<title level="a" type="main">Patient-reported outcomes improve with etanercept plus methotrexate in active early rheumatoid arthritis and the improvement is strongly associated with remission: the COMET trial</title>
		<author>
			<persName><forename type="first">J</forename><surname>Kekow</surname></persName>
		</author>
		<author>
			<persName><forename type="first">R</forename><forename type="middle">J</forename><surname>Moots</surname></persName>
		</author>
		<author>
			<persName><forename type="first">P</forename><surname>Emery</surname></persName>
		</author>
		<idno type="DOI">10.1136/ard.2008.102509</idno>
	</analytic>
	<monogr>
		<title level="j">Ann Rheum Dis</title>
		<imprint>
			<biblScope unit="volume">69</biblScope>
			<biblScope unit="page" from="222" to="225" />
			<date type="published" when="2010">2010</date>
		</imprint>
	</monogr>
</biblStruct>

<biblStruct xml:id="b45">
	<analytic>
		<title level="a" type="main">The effects of golimumab on radiographic progression in rheumatoid arthritis: results of randomized controlled studies of golimumab before methotrexate therapy and golimumab after methotrexate therapy</title>
		<author>
			<persName><forename type="first">P</forename><surname>Emery</surname></persName>
		</author>
		<author>
			<persName><forename type="first">R</forename><surname>Fleischmann</surname></persName>
		</author>
		<author>
			<persName><forename type="first">D</forename><surname>Van Der Heijde</surname></persName>
		</author>
		<idno type="DOI">10.1002/art.30263</idno>
	</analytic>
	<monogr>
		<title level="j">Arthritis Rheum</title>
		<imprint>
			<biblScope unit="volume">63</biblScope>
			<biblScope unit="page" from="1200" to="1210" />
			<date type="published" when="2011">2011</date>
		</imprint>
	</monogr>
</biblStruct>

<biblStruct xml:id="b46">
	<analytic>
		<title level="a" type="main">Health-related quality of life outcomes of adalimumab for patients with early rheumatoid arthritis: results from a randomized multicenter study</title>
		<author>
			<persName><forename type="first">V</forename><surname>Strand</surname></persName>
		</author>
		<author>
			<persName><forename type="first">A</forename><forename type="middle">M</forename><surname>Rentz</surname></persName>
		</author>
		<author>
			<persName><forename type="first">M</forename><forename type="middle">A</forename><surname>Cifaldi</surname></persName>
		</author>
		<idno type="DOI">10.3899/jrheum.101161</idno>
	</analytic>
	<monogr>
		<title level="j">J Rheumatol</title>
		<imprint>
			<biblScope unit="volume">39</biblScope>
			<biblScope unit="page" from="63" to="72" />
			<date type="published" when="2012">2012</date>
		</imprint>
	</monogr>
</biblStruct>

<biblStruct xml:id="b47">
	<analytic>
		<title level="a" type="main">Sustained benefit in rheumatoid arthritis following one course of rituximab: improvements in physical function over 2 years</title>
		<author>
			<persName><forename type="first">V</forename><surname>Strand</surname></persName>
		</author>
		<author>
			<persName><forename type="first">A</forename><surname>Balbir-Gurman</surname></persName>
		</author>
		<author>
			<persName><forename type="first">K</forename><surname>Pavelka</surname></persName>
		</author>
		<idno type="DOI">10.1093/rheumatology/kel358</idno>
	</analytic>
	<monogr>
		<title level="j">Rheumatology (Oxford)</title>
		<imprint>
			<biblScope unit="volume">45</biblScope>
			<biblScope unit="page" from="1505" to="1513" />
			<date type="published" when="2006">2006</date>
		</imprint>
	</monogr>
</biblStruct>

<biblStruct xml:id="b48">
	<analytic>
		<title level="a" type="main">Treatment of rheumatoid arthritis patients with abatacept and methotrexate significantly improved health-related quality of life</title>
		<author>
			<persName><forename type="first">P</forename><surname>Emery</surname></persName>
		</author>
		<author>
			<persName><forename type="first">M</forename><surname>Kosinski</surname></persName>
		</author>
		<author>
			<persName><forename type="first">T</forename><surname>Li</surname></persName>
		</author>
	</analytic>
	<monogr>
		<title level="j">J Rheumatol</title>
		<imprint>
			<biblScope unit="volume">33</biblScope>
			<biblScope unit="page" from="681" to="689" />
			<date type="published" when="2006">2006</date>
		</imprint>
	</monogr>
</biblStruct>

<biblStruct xml:id="b49">
	<analytic>
		<title level="a" type="main">Abatacept improves both the physical and mental health of patients with rheumatoid arthritis who have inadequate response to methotrexate treatment</title>
		<author>
			<persName><forename type="first">A</forename><forename type="middle">S</forename><surname>Russell</surname></persName>
		</author>
		<author>
			<persName><forename type="first">G</forename><forename type="middle">V</forename><surname>Wallenstein</surname></persName>
		</author>
		<author>
			<persName><forename type="first">T</forename><surname>Li</surname></persName>
		</author>
		<idno type="DOI">10.1136/ard.2006.057018</idno>
	</analytic>
	<monogr>
		<title level="j">Ann Rheum Dis</title>
		<imprint>
			<biblScope unit="volume">66</biblScope>
			<biblScope unit="page" from="189" to="194" />
			<date type="published" when="2007">2007</date>
		</imprint>
	</monogr>
</biblStruct>

<biblStruct xml:id="b50">
	<analytic>
		<title level="a" type="main">Efficacy and safety of subcutaneous golimumab in methotrexate-naive patients with rheumatoid arthritis: five-year results of a randomized clinical trial</title>
		<author>
			<persName><forename type="first">P</forename><surname>Emery</surname></persName>
		</author>
		<author>
			<persName><forename type="first">R</forename><forename type="middle">M</forename><surname>Fleischmann</surname></persName>
		</author>
		<author>
			<persName><forename type="first">I</forename><surname>Strusberg</surname></persName>
		</author>
		<idno type="DOI">10.1002/acr.22759</idno>
	</analytic>
	<monogr>
		<title level="j">Arthritis Care Res</title>
		<imprint>
			<biblScope unit="volume">68</biblScope>
			<biblScope unit="page" from="744" to="752" />
			<date type="published" when="2016">2016</date>
		</imprint>
	</monogr>
</biblStruct>

<biblStruct xml:id="b51">
	<monogr>
		<title level="m" type="main">How to score version two of the SF-36 health survey</title>
		<author>
			<persName><forename type="first">J</forename><forename type="middle">E</forename><surname>Ware</surname></persName>
		</author>
		<author>
			<persName><forename type="first">M</forename><surname>Kosinski</surname></persName>
		</author>
		<author>
			<persName><forename type="first">J</forename><forename type="middle">E</forename><surname>Dewey</surname></persName>
		</author>
		<imprint>
			<date type="published" when="2000">2000</date>
			<publisher>QualityMetric</publisher>
			<pubPlace>Lincoln (RI</pubPlace>
		</imprint>
	</monogr>
	<note>Incorporated</note>
</biblStruct>

<biblStruct xml:id="b52">
	<analytic>
		<title level="a" type="main">Use of &quot;spydergrams&quot; to present and interpret SF-36 health-related quality of life data across rheumatic diseases</title>
		<author>
			<persName><forename type="first">V</forename><surname>Strand</surname></persName>
		</author>
		<author>
			<persName><forename type="first">B</forename><surname>Crawford</surname></persName>
		</author>
		<author>
			<persName><forename type="first">J</forename><surname>Singh</surname></persName>
		</author>
		<idno type="DOI">10.1136/ard.2009.115550</idno>
	</analytic>
	<monogr>
		<title level="j">Ann Rheum Dis</title>
		<imprint>
			<biblScope unit="volume">68</biblScope>
			<biblScope unit="page" from="1800" to="1804" />
			<date type="published" when="2009">2009</date>
		</imprint>
	</monogr>
</biblStruct>

<biblStruct xml:id="b53">
	<analytic>
		<title/>
		<author>
			<persName><forename type="first">V</forename><surname>Strand</surname></persName>
		</author>
		<idno type="DOI">10.1136/rmdopen-2016-00030811</idno>
	</analytic>
	<monogr>
		<title level="j">Open</title>
		<imprint>
			<biblScope unit="volume">2</biblScope>
			<biblScope unit="page">e000308</biblScope>
			<date type="published" when="2016">2016</date>
		</imprint>
	</monogr>
</biblStruct>

<biblStruct xml:id="b54">
	<monogr>
		<title/>
		<idno type="DOI">10.1136/rmdopen-2016-000308on28</idno>
		<ptr target="http://rmdopen.bmj.com/RMDOpen" />
		<imprint>
			<date type="published" when="2016-09">September 2016</date>
		</imprint>
	</monogr>
	<note>Rheumatoid arthritis on May. Downloaded from</note>
</biblStruct>

				</listBibl>
			</div>
		</back>
	</text>
</TEI>
